Linking systemic angiogenic factors (VEGF, angiogenin, TIMP-2) and Doppler ultrasound to anti-inflammatory treatment in rheumatoid arthritis
Authors:
- 1 May 2013
- journal article
- Published by Elsevier in Joint Bone Spine
- Vol. 80 (3) , 270-273
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Phage Display of Tissue Inhibitor of Metalloproteinases-2 (TIMP-2)Journal of Biological Chemistry, 2011
- New insights in synovial angiogenesisJoint Bone Spine, 2010
- Targeting angiogenesis: progress with anti-VEGF treatment with large moleculesNature Reviews Clinical Oncology, 2009
- Elevated angiogenin levels in synovial fluid from patients with inflammatory arthritis and secretion of angiogenin by cultured synovial fibroblastsClinical and Experimental Immunology, 2003
- Vascular endothelial growth factor expression by activated synovial leukocytes in rheumatoid arthritis: Critical involvement of the interaction with synovial fibroblastsArthritis & Rheumatism, 2001
- The angiogenins: An emerging family of ribonuclease related proteins with diverse cellular functionsAngiogenesis, 1999
- Angiogenesis and arthritisRheumatology, 1999
- Angiogenesis: Implications for rheumatoid arthritisArthritis & Rheumatism, 1998
- Vascular Endothelial Growth Factor in Patients with Rheumatoid ArthritisScandinavian Journal of Rheumatology, 1998
- Angiogenesis: a critical process in the pathogenesis of RA--a role for VEGF?Rheumatology, 1996